179 related articles for article (PubMed ID: 28895096)
1. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
Kashiwagi T; Okada Y; Nomoto K
Paediatr Drugs; 2018 Feb; 20(1):97-104. PubMed ID: 28895096
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
Eur J Pediatr; 2018 Jun; 177(6):903-911. PubMed ID: 29651734
[TBL] [Abstract][Full Text] [Related]
3. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
[TBL] [Abstract][Full Text] [Related]
4. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
6. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
Turti TV; Baibarina EN; Degtiareva EA; Keshishyan ES; Lobzin YV; Namazova-Вaranova LS; Prodeus AP; Gudkov KM; Kruglova AI; Schulz GA; Notario GF
BMC Res Notes; 2012 Sep; 5():484. PubMed ID: 22943074
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
[TBL] [Abstract][Full Text] [Related]
9. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
11. Utilization and efficacy of palivizumab for children with Down syndrome.
Kimura T; Takeuchi M; Kawakami K
Pediatr Int; 2020 Jun; 62(6):677-682. PubMed ID: 31961027
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
[TBL] [Abstract][Full Text] [Related]
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
17. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.
Mori M; Watabe S; Taguchi T; Hasegawa H; Ishige M; Tanuma N; Hirakawa A; Koike R; Kusuda S
BMC Pediatr; 2021 Mar; 21(1):106. PubMed ID: 33653291
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
19. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
Luna MS; Manzoni P; Paes B; Baraldi E; Cossey V; Kugelman A; Chawla R; Dotta A; Rodríguez Fernández R; Resch B; Carbonell-Estrany X
Paediatr Respir Rev; 2020 Feb; 33():35-44. PubMed ID: 31060948
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]